Remicade

Known as: Remicade [brand name] 
brand name of infliximab a drug used to treat autoimmune disorders
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

infliximab
infliximab 100 MG Injection [Remicade]infliximab Injection [Remicade]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
OBJECTIVE The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima (CT-P13) with the originator drug… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
BACKGROUND AND AIMS The biosimilar of Remicade®, CT-P13, recently entered the European market. Clinical data on switching from… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
BACKGROUND Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
Adverse events after intravitreal infliximab (Remicade).
PURPOSE To determine the tolerability of intravitreal infliximab (Remicade) in patients with refractory diabetic macular edema or… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.
Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the… (More)
Is this relevant?
2004
2004
Anti-TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosis
Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Remicade as TNF suppressor in patients with myelodysplastic syndromes.
Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.
OBJECTIVE When one TNFalpha blocker (etanercept or infliximab) has failed, to determine whether it makes sense to treat patients… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
OBJECTIVE The cost per quality-adjusted life-year (QALY) of infliximab (Remicade) treatment in rheumatoid arthritis (RA) was… (More)
Is this relevant?
2003
2003
Retinal Vein Thrombosis After Infliximab (Remicade) Treatment for Crohn's Disease
TO THE EDITOR: We report an unusual case of a 45-yrold woman who developed branch retinal vein thrombosis after receiving… (More)
  • figure 1
Is this relevant?